Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of AbbVie Inc.. A complete text table follows the diagram.
Skyrizi and Rinvoq generated $6.6 billion as Humira contracted, but a $2.4 billion success-linked liability remeasurement compressed reported earnings
Swipe to explore
All flow values are directly reported or exact sums of reported product revenue within AbbVie's disclosed therapeutic groupings. The filing reports $2.306 billion of net other expense, including a $2.387 billion contingent-consideration fair-value charge.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Immunology | 1 | $7.3B | Skyrizi, Rinvoq and Humira |
| Neuroscience | 1 | $2.9B | Vraylar, therapeutic Botox and migraine portfolio |
| Oncology | 1 | $1.6B | Venclexta led the franchise |
| Aesthetics | 1 | $1.2B | Cosmetic Botox, Juvederm and other aesthetics |
| Other key products & all other | 1 | $2.0B | Mavyret, Creon, Linzess and portfolio tail |
| Net revenue | 2 | $15.0B | Up 12.4% year over year |
| Gross margin | 3 | $10.8B | 72% of revenue |
| Cost of products sold | 3 | $4.2B | Includes $1.7B intangible amortization |
| Operating earnings | 4 | $4.0B | 26.6% operating margin |
| Selling, general & administrative | 4 | $3.6B | 24% of revenue |
| Research & development | 4 | $2.5B | Up 20%; roughly 90 pipeline programs |
| Acquired IPR&D & milestones | 4 | $744M | Includes $650M RemeGen license charge |
| Earnings before income tax | 5 | $1.0B | After financing and fair-value charges |
| Net interest expense | 5 | $645M | Debt financing cost |
| Other expense, net | 5 | $2.3B | Mostly contingent-consideration remeasurement |
| Net earnings | 6 | $697M | 4.6% of revenue |
| Income tax | 6 | $342M | 33% effective rate |
| Earnings attributable to AbbVie | 7 | $695M | $0.39 diluted EPS |
| Noncontrolling interest | 7 | $2M | Minority ownership claim |
| From | To | Value |
|---|---|---|
| Immunology | Net revenue | $7.3B |
| Neuroscience | Net revenue | $2.9B |
| Oncology | Net revenue | $1.6B |
| Aesthetics | Net revenue | $1.2B |
| Other key products & all other | Net revenue | $2.0B |
| Net revenue | Gross margin | $10.8B |
| Net revenue | Cost of products sold | $4.2B |
| Gross margin | Operating earnings | $4.0B |
| Gross margin | Selling, general & administrative | $3.6B |
| Gross margin | Research & development | $2.5B |
| Gross margin | Acquired IPR&D & milestones | $744M |
| Operating earnings | Earnings before income tax | $1.0B |
| Operating earnings | Net interest expense | $645M |
| Operating earnings | Other expense, net | $2.3B |
| Earnings before income tax | Net earnings | $697M |
| Earnings before income tax | Income tax | $342M |
| Net earnings | Earnings attributable to AbbVie | $695M |
| Net earnings | Noncontrolling interest | $2M |